Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Schenk

Showing results (41-50 of 56) with videos related to

Pageof 6
Sort By:
European Journal of Pain (London, England)|July 3, 2009
Referral practices in patients suffering from non-malignant chronic painErika Schulte, Katja Hermann, Anne Berghöfer, et al.
Annals of Internal Medicine|May 5, 2015
Low-molecular-weight heparin for women with unexplained recurrent pregnancy loss: a multicenter trial with a minimization randomization schemeEkkehard Schleussner, Gabriele Kamin, Gregor Seliger, et al.
British Journal of Cancer|July 11, 2018
Randomised phase II trial to investigate catumaxomab (anti-EpCAM × anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric cancerMaren Knödler, Justus Körfer, Volker Kunzmann, et al.
The European Respiratory Journal|March 21, 2015
Erlotinib and bevacizumab versus cisplatin, gemcitabine and bevacizumab in unselected nonsquamous nonsmall cell lung cancerMichael Thomas, Jürgen Fischer, Stefan Andreas, et al.
European Journal of Cancer (Oxford, England : 1990)|August 8, 2022
First-line fluoropyrimidine plus bevacizumab followed by irinotecan-escalation versus initial fluoropyrimidine, irinotecan and bevacizumab in patients with metastatic colorectal cancer - Final survival and per-protocol analysis of the randomised XELAVIRI trial (AIO KRK 0110)Arndt Stahler, Dominik P Modest, Ludwig Fischer von Weikersthal, et al.
European Journal of Cancer (Oxford, England : 1990)|September 10, 2021
Consensus molecular subtypes in metastatic colorectal cancer treated with sequential versus combined fluoropyrimidine, bevacizumab and irinotecan (XELAVIRI trial)Arndt Stahler, Volker Heinemann, Veronika Schuster, et al.
European Journal of Cancer (Oxford, England : 1990)|March 1, 2021
Gender-dependent survival benefit from first-line irinotecan in metastatic colorectal cancer. Subgroup analysis of a phase III trial (XELAVIRI-study, AIO-KRK-0110)Kathrin Heinrich, Dominik P Modest, Ingrid Ricard, et al.
European Journal of Cancer (Oxford, England : 1990)|August 5, 2020
Impact of age on efficacy and early mortality of initial sequential treatment versus upfront combination chemotherapy in patients with metastatic colorectal cancer: a subgroup analysis of a phase III trial (AIO KRK0110, XELAVIRI study)Annika Kurreck, Volker Heinemann, Ludwig Fischer von Weikersthal, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|October 4, 2023
Three-month life expectancy as inclusion criterion for clinical trials in advanced pancreatic cancer: is it really a valid tool for patient selection?Lena Weiss, Volker Heinemann, Laura E Fischer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 3, 2018
Sequential Versus Combination Therapy of Metastatic Colorectal Cancer Using Fluoropyrimidines, Irinotecan, and Bevacizumab: A Randomized, Controlled Study-XELAVIRI (AIO KRK0110)Dominik Paul Modest, Ludwig Fischer von Weikersthal, Thomas Decker, et al.
Pageof 6

Showing results (41-50 of 56) with videos related to

Sort By:
Pageof 6
European Journal of Pain (London, England)|July 3, 2009
Referral practices in patients suffering from non-malignant chronic painErika Schulte, Katja Hermann, Anne Berghöfer, et al.
Annals of Internal Medicine|May 5, 2015
Low-molecular-weight heparin for women with unexplained recurrent pregnancy loss: a multicenter trial with a minimization randomization schemeEkkehard Schleussner, Gabriele Kamin, Gregor Seliger, et al.
British Journal of Cancer|July 11, 2018
Randomised phase II trial to investigate catumaxomab (anti-EpCAM × anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric cancerMaren Knödler, Justus Körfer, Volker Kunzmann, et al.
The European Respiratory Journal|March 21, 2015
Erlotinib and bevacizumab versus cisplatin, gemcitabine and bevacizumab in unselected nonsquamous nonsmall cell lung cancerMichael Thomas, Jürgen Fischer, Stefan Andreas, et al.
European Journal of Cancer (Oxford, England : 1990)|August 8, 2022
First-line fluoropyrimidine plus bevacizumab followed by irinotecan-escalation versus initial fluoropyrimidine, irinotecan and bevacizumab in patients with metastatic colorectal cancer - Final survival and per-protocol analysis of the randomised XELAVIRI trial (AIO KRK 0110)Arndt Stahler, Dominik P Modest, Ludwig Fischer von Weikersthal, et al.
European Journal of Cancer (Oxford, England : 1990)|September 10, 2021
Consensus molecular subtypes in metastatic colorectal cancer treated with sequential versus combined fluoropyrimidine, bevacizumab and irinotecan (XELAVIRI trial)Arndt Stahler, Volker Heinemann, Veronika Schuster, et al.
European Journal of Cancer (Oxford, England : 1990)|March 1, 2021
Gender-dependent survival benefit from first-line irinotecan in metastatic colorectal cancer. Subgroup analysis of a phase III trial (XELAVIRI-study, AIO-KRK-0110)Kathrin Heinrich, Dominik P Modest, Ingrid Ricard, et al.
European Journal of Cancer (Oxford, England : 1990)|August 5, 2020
Impact of age on efficacy and early mortality of initial sequential treatment versus upfront combination chemotherapy in patients with metastatic colorectal cancer: a subgroup analysis of a phase III trial (AIO KRK0110, XELAVIRI study)Annika Kurreck, Volker Heinemann, Ludwig Fischer von Weikersthal, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|October 4, 2023
Three-month life expectancy as inclusion criterion for clinical trials in advanced pancreatic cancer: is it really a valid tool for patient selection?Lena Weiss, Volker Heinemann, Laura E Fischer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 3, 2018
Sequential Versus Combination Therapy of Metastatic Colorectal Cancer Using Fluoropyrimidines, Irinotecan, and Bevacizumab: A Randomized, Controlled Study-XELAVIRI (AIO KRK0110)Dominik Paul Modest, Ludwig Fischer von Weikersthal, Thomas Decker, et al.
Pageof 6